Our Publications - Cancer Treatment | Theranostics Australia

Our Publications

Enter keywords within the Search Bar below to segment, categorise and narrow publication results.

Example Keywords: NET, Prostate, Metastatic, Lutetium-177, Rituximab, PSMA, Octreotate etc.

Alternatively, use the Field Ordering Arrows in the table header to order publications by Title, Author, Journal and Date.

 

TitleAuthor/sJournalDate
Thyroid Cancer Treatment - Audit Report Lombard M, Lenzo N, Lisewski DUniversity of Notre Dame Australia2016 December
Ga-68 PSMA PET CT in Rising PSA Post-Definitive TreatmentLenzo N, Askandoran M, Skelly L, Meyrick D, Henderson ABJUI2016 August
Gallium-68 PSMA PET CT and Lutetium-177 PSMA in Prostate CancerLenzo NP, Meyrick D, Cardaci J, Yeo S, Henderson A, Lim TAsia-Pacific Journal of Clinical Oncology2016 July
Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience.Kesavan Murali and Turner J. HarveyCancer Biotherapy and Radiopharmaceuticals2016 July
Epidemiology of ductal carcinoma in situ in Western Australia: implications for surgical margins and management.Butler-Henderson K, Lee AH, Lenzo NP, Price RI.Breast Cancer2015 November
Phase II study of first-line (131)I-rituximab radioimmunotherapy in follicular non-Hodgkin lymphoma and prognostic (18)F-fluorodeoxyglucose positron emission tomography.McQuillan AD, Macdonald WB, Turner JH.Leuk Lymphoma2015 May
Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy.Claringbold PG, Turner JH.Neuroendocrinology2015 June
NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): A Phase I Study.Claringbold PG, Turner JH.Cancer Biother Radiopharm 2015 August
Personalized dosimetry of 131I-rituximab radioimmunotherapy of non-hodgkin lymphoma defined by pharmacokinetics in bone marrow and blood.Boucek JA, Turner JHCancer Biother Radiopharm2014 February
Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study.Gibbs P, Gebski V, Van Buskirk M, Thurston K, Cade DN, Van Hazel GA; SIRFLOX Study Group.BMC Cancer2014 December
Positron emission tomography-positive thyroid nodules: rate of malignancy and histological features.Flukes S, Lenzo N, Moschilla G, Sader C.ANZ Journal of Surgery2014 August
Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.Kesavan M, Claringbold PG, Turner JH.Neuroendocrinology2014
Radiation safety of outpatient 177Lu-octreotate radiopeptide therapy of neuroendocrine tumors.Calais PJ, Turner JH.Annals of Nuclear Medicine2014
Standard Operating Procedure for In-house Preparation of (131)I-rituximab for Radioimmunotherapy of Non-Hodgkin's Lymphoma.Pickford MD, Turner JHWorld Journal of Nuclear Medicine2012 September
Standard Operating Procedure for Prospective Individualised Dosimetry for ([131])I-rituximab Radioimmunotherapy of Non-Hodgkin's Lymphoma.Calais PJ, Turner JHWorld Journal of Nuclear Medicine2012 September
Global WARMTH for Patients with Cancer.Turner JHWorld Journal of Nuclear Medicine2012 September
Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma.Kruger PC, Cooney JP, Turner JHCancer Biother Radiopharm2012 November
Outpatient 131I-rituximab radioimmunotherapy for non-Hodgkin lymphoma: a study in safety.Calais PJ, Turner JHClinical Nuclear Medicine2012 November
Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors.Claringbold PG, Price RA, Turner JHCancer Biother Radiopharm2012 November
Perspective: multimodality radionuclide therapy of progressive disseminated lymphoma and neuroendocrine tumors as a paradigm for cancer control.Turner JHCancer Biother Radiopharm2012 November
Outpatient therapeutic nuclear oncology.Turner JHAnnals of Nuclear Medicine2012 May
Systemic arterial inflammation, measured with 18FDG-PET, is common amongst subjects with both recent and prior cerebrovascular disease.Beer CD, Potter K, Lenzo N, Blacker D, Arnolda LF, Hankey GJ, Puddey IBClinical Neurology and Neurosurgery2012 July
Management of fear of radiation exposure in carers of outpatients treated with iodine-131.Calais PJ, Page AC, Turner JHAnnals of Nuclear Medicine2012 July
Automated module radiolabeling of peptides and antibodies with gallium-68, lutetium-177 and iodine-131.De Decker M,Turner JHCancer Biother Radiopharm2012 February
¹⁸F-Fluoromethylcholine (FCH) PET imaging in patients with castration-resistant prostate cancer: prospective comparison with standard imaging.McCarthy M, Siew T, Campbell A, Lenzo N, Spry N, Vivian J, Morandeau LEuropean Journal of Nuclear Medicine and Molecular Imaging2011 January
Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients.Leahy MF, Turner JHBlood2011 January
Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours.Claringbold PG, Brayshaw PA, Price RA, Turner JHEuropean Journal of Nuclear Medicine and Molecular Imaging2011 February
Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma.Ong GS, Henley DE, Hurley D, Turner JH, Claringbold PG, Fegan PGEuropean Journal of Endocrinology2010 May
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging.Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Fripp J, Tochon-Danguy H, Morandeau L, O’Keefe G, Price R, Raniga P, Robins P, Acosta O, Lenzo N, Szoeke C, Salvado O, Head R, Martins R, Masters CL, Ames D, Villemagne VL.Neurobiology of Aging2010 August
Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer: results of a multicentre prospective study.Chatterton BE, Ho Shon I, Baldey A, Lenzo N, Patrikeos A, Kelley B, Wong D, Ramshaw JE, Scott AMEuropean Journal of Nuclear Medicine and Molecular2009 March
Effect of long-term homocysteine reduction with B vitamins on arterial wall inflammation assessed by fluorodeoxyglucose positron emission tomography: a randomised double-blind, placebo-controlled trial.Potter K, Lenzo N, Eikelboom JW, Arnolda LF, Beer C, Hankey GJCerebrovascular Diseases2009 February
The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease.Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P, Lautenschlager NT, Lenzo N, Martins RN, Maruff P, Masters C, Milner A, Pike K, Rowe C, Savage G, Szoeke C, Taddei K, Villemagne V, Woodward M, Ames D; AIBL Research Group.International Psychogeriatrics2009 August
Repeat treatment with iodine-131-rituximab is safe and effective in patients with relapsed indolent B-cell non-Hodgkin's lymphoma who had previously responded to iodine-131-rituximab.Bishton MJ, Leahy MF, Hicks RJ, Turner JH, McQuillan AD, Seymour JFAnnals of Oncology2008 September
18F-fluorodeoxyglucose positron emission tomography imaging in brain tumours: the Western Australia positron emission tomography/cyclotron service experience.McCarthy M, Yuan JB, Campbell A, Lenzo NP, Butler-Henderson KJournal of Medical Imaging and Radiation Oncology2008 December
Fluoromethylcholine PET in recurrent multifocal hepatoma.Lenzo NP, Anderson J, Campbell A, Morandeau L, De Grado TRAustralasian Radiology2007 December
Pre-clinical evaluation of 2,3-dimercaptosuccinic acid as a radiation nephrotoxicity protective agent during radiopeptide therapy of neuroendocrine malignancy.Moorin RE, Meyrick DP, Rose ANuclear Medicine Communications2007 April
Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma.Leahy MF, Seymour JF, Hicks RJ, Turner JHJournal of Clinical Oncology2006 September
Validation of prospective whole-body bone marrow dosimetry by SPECT/CT multimodality imaging in (131)I-anti-CD20 rituximab radioimmunotherapy of non-Hodgkin's lymphoma.Boucek JA, Turner JHEuropean Journal of Nuclear Medicine and Molecular2005 April
Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer.Van Hazel G, Blackwell A, Anderson J, Price D, Moroz P, Bower G, Cardaci G, Gray BJournal of Clinical Oncology2004 November
A kit formulation for the preparation of 188Re-lipiodol: preclinical studies and preliminary therapeutic evaluation in patients with unresectable hepatocellular carcinoma.Boschi A, Uccelli L, Duatti A, Colamussi P, Cittanti C, Filice A, Rose AH, Martindale AA, Claringbold PG, Kearney D, Galeotti R, Turner JH, Giganti MNuclear Medicine Communications2004 July
131I-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital.Turner JH, Martindale AA, Boucek J, Claringbold PG, Leahy MFCancer Biother Radiopharm2003 August
Prospective 153Sm-EDTMP therapy dosimetry by whole-body scintigraphy.Cameron PJ, Klemp PF, Martindale AA, Turner JHNuclear Medicine Communications1999 July

Reference: PubMed